#her2 breast cancer

Monoclonal antibody delays disease progression in people with previously treated HER2-positive tumors.

However, adjuvant chemotherapy does improve outcomes for premenopausal women with early-stage cancer that has spread to their lymph nodes.

The honeybee’s sting contains a compound that kills hard-to-treat breast cancer cells quickly.

The oral targeted therapy lowered the risk of relapse in a late-stage study.

Here are latest arrivals approved by the Food and Drug Administration.

New injectable combination can be administered by health care providers outside medical centers.

A new randomized study sought to clarify results from previous studies that suggested there would be a benefit from such local treatment.

Last year, the FDA approved three new antibody-drug conjugates for treating cancer.

Tucatinib fights breast cancer that spreads to the brain

Former Air Force senior master sergeant Sheila McGlown, 53, has metastatic breast cancer. She lives with her husband near St. Louis.

“In the era of targeted therapy, it is critical to know that a therapy is the right choice and is going to be effective.”

A third of people treated with Nerlynx plus capecitabine experienced remission.

In both clinical trials, women whose cancers had spread to the brain were eligible to participate.